Weight Gain Common in Childhood Brain Tumor Survivors medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Recognizing the current global and national focus on the development and distribution of COVID-19 vaccines, the March 2021 installment of the President’s Speaker Series will present a moderated panel of leading medical, pharmaceutical, and biotechnology experts who will share their professional knowledge and experience with COVID-19 vaccines and examine what society might expect from vaccines in the future.
Stéphane Bancel, chief executive officer of Moderna, Stephen M. Hahn, former commissioner of food and drugs at the US Food and Drug Administration, and Jonathan B. Perlin, president of the Clinical Services Group and chief medical officer of HCA Healthcare, will present “Vaccines: Where Are We and Where Are We Going?” via Zoom on Monday, March 29, at 5 PM PDT. Dee Anna Smith (’86), CEO of Sarah Cannon, the Cancer Institute of HCA Healthcare, and chair of the Pepperdine Board of Regents, will moderate the discussion.
Published: Mar 11, 2021 By Alex Keown
Saniona, a rare disease-focused company based in Sweden, received feedback from the U.S. Food and Drug Administration (FDA) on a path forward for its hypothalamic obesity (HO) drug Tesomet. Based on guidance from the regulatory agency, Saniona is planning a Phase IIb study in this indication in the first half of this year.
“There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger,” Rudolf Baumgartner, Chief Medical Officer and Head of Clinical Development at Saniona said in a statement. “We are encouraged by this feedback from the FDA and look forward to continuing a constructive dialogue with them as we prepare to initiate our Phase IIb clinical trial with Tesomet.”
Message :
Required fields AFM24 preclinical in vivo data will be presented as a poster Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 Affimed N.V. (Nasdaq: AFMD), a
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, announced today that preclinical
anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) )
AFM24 have been accepted for e-poster presentation at the American
Association for Cancer Research (AACR) Virtual Annual Meeting I, being
held on April 10-15. In addition, early data from a Phase 1 study evaluating AFM13 preloaded
Palliative Care for Patients With Dementia: When to Refer? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.